



Chantal PICHON (short CV as of August 2022)

POSITIONS AND EMPLOYMENT

2022: Senior member of “Institut Universitaire de France” (<https://www.iufrance.fr/>): “Chair of Innovation”

2018: Professor of Outstanding class, 2nd rank (highest rank for French universities).

2014: Professor of Outstanding class 1st rank.

2010: Professor of 1st Class (equivalent to Full Professor).

2005: Professor 2nd class in Molecular and Cell Biology (French university rank).

1994-2000: Assistant Professor at University of Orléans & Center for Molecular Biophysics-Orléans France.

09/1991-01/1993: Post-doctoral training at Agricultural Fund Research Council in Cambridge (UK).

1988-1991: PhD training at Institute of Chemical Biology (CNRS and Marseille University). Higher education and Research French Ministry funding.

RESEARCH INTERESTS

C. Pichon is conducting interdisciplinary projects based on chemistry and molecular and cell biology with a crosstalk between basic and applied researches. C. Pichon’s main research activities are dedicated mainly to the use of nucleic acids as therapeutics. These last years, she is particularly interested in messenger RNAs vaccines and therapeutics. She is developing innovative formulations for their delivery for various applications: mucosal vaccination, cell-based therapies and protein replacement therapy. C. Pichon has patented mRNA bioproduction technology based on a tailor-made yeast-based mRNA factory platform, a complete shift of paradigm compared to *in vitro* production and a revolutionary new use of yeast. She envisions to build an economically sustainable biotechnology process for production of high-quality mRNA therapeutics opening their use in different applications. Social disparities between and within European countries and all over the world that are negatively associated with access to new biopharmaceuticals as mRNAs.

SUPERVISING ACTIVITIES

Students and Post-Doc fellows in total: 16 PhD students, 12 Post-doc fellows.

Lab members composition of the department: 30.

SCIENTIFIC PUBLICATIONS AND DISSEMINATION

167 peer-reviewed publications (H-index of 41 WOS, ORCID 0000-0003-3161-3937 Scopus ID: 7004581546); 11 filed patents: 2 patents under licenses. 52 invited keynote lectures at national and international conferences and >150 communications.

GRANTS

26 grants with 17 as PI (ANR, AFM, Ligue National contre le Cancer, FRM, Région Centre Val de Loire ARD2020, SATT, FUI, INCA, PHC, FP7 REGPOT 2012, FP7 Health Innovation, FEDER2020, ANR Grand challenge Biomedicines and Bioproduction, EIC PathFinder, Private fundings: Polyplus transfection, Polytheragene, LVMH, Gimopharm, Alban Mueller SA, Sanofi R&D, Sanofi Pasteur. Total amount of secured funding: ~9.1M€.

ADMINISTRATION DUTIES

University of Orléans

2018: Vice-President of Ethical Committee of Region Centre Val de Loire.

Since 2013: Member of administration council of Faculty of Sciences and Expert Committee of Biology and Biochemistry disciplines.

2012-2018: Elected Director of Biological Sciences and Chemistry for Life Institute of Orléans University. The institute comprises six research units (CBM, ICOA, INEM, LBLGC, I3MTO, CIAMS) and 4 Masters programs.

2012- 2018: Member of board of Directors of Orléans University; Member of Administration council of Collegium of Sciences.

2011-2016: Member of Health, Biological Sciences and Chemistry for Life Doctoral school directory of Orléans-

Tours Academia.

2008-2012: Member of Scientific council of University of Orléans; nominated Member of Pedagogic committee and financial Committee of Faculty of Sciences.

Since 2008: Nominated as Head of Life Master studies.

Center for Molecular Biophysics, UPR 4301 (CBM)

2017- 2022: Head of Cell Biology, Pharmacological targets and Innovative therapies department at Center for Molecular Biophysics UPR 4301 CNRS: 30 permanent staff members divided in 5 groups: Cell Signaling and Neurofibromatosis; Apoptosis and autophagy; Cell microenvironment and Receptors pharmacology; RNA biology; Innovative therapies and Nanomedicine.

2012- : Member of CBM Scientific Committee.

2012-2016: Coordinator of Cell Biology and new cellular targets department (4 teams: Programmed cell death, Cell Signalling and neurofibromatosis, Microenvironment and pharmacological targets, Nucleic acids transfer by non-viral systems).

National/international mandates and expertise activities:

2021: Elected member of CNRS National Committee of 28th section (Pharmacology, biotechnology, imaging and bioengineering).

2019: Nominated member of National Strategic Committee of Bioproduction pharmaceutical sectors (General Secretary of Innovation).

2017: Scientific Board of French Society of Nanomedicine.

Since 2016: Nominated Board member of Nanoagents and Synthetic formulations committee of American Society of Gene and Cell therapy.

2015- : Expert of H2020 FET-OPEN program, ERC starting and consolidator grants, FWO (Flanders), ISF (Israel), ANR (France).

2013-: Member of Ethical Committee of Région Centre Val de Loire.

2012-2016: Member of Administration council of Pole Pharma, a cluster of Pharmavalley competitive pole.

2012-2016: Elected member of CNRS National Committee of 28th section (Pharmacology, biotechnology, imaging and bioengineering).

2012-2013: Nominated member of National Council of University section n°64 (Biochemistry, Molecular biology and Biotechnology).

2008-2012: Elected member of CNRS National Committee of 21th section (Molecular and Structural basis of life).